

Edgar Filing: ALSTOM - Form 6-K

ALSTOM
Form 6-K
August 11, 2004

FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

For the month of August 2004

Commission File Number: 1-14836

ALSTOM

(Translation of registrant's name into English)

25, avenue Kléber, 75116 Paris, France

(Address of principal executive offices)

Indicate by check mark whether the Registrant files or will file annual reports
under cover of Form 20-F or Form 40-F

Form 20-F X

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):

Yes

No X

Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):

Yes

No X

Indicate by check mark whether the Registrant, by furnishing the information
contained in this Form, is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934

Yes

No X

If "Yes" is marked, indicate below the file number assigned to the Registrant in
connection with Rule 12g3-2(b)

Edgar Filing: ALSTOM - Form 6-K

10 August 2004

ALSTOM'S ADR LISTING ON NYSE

ALSTOM ordinary shares currently are listed on the Paris Stock Exchange and American Depositary Receipts (ADRs) representing approximately 30 million ALSTOM ordinary shares currently are listed on the New York Stock Exchange. The Company delisted its UK Depositary Receipts from the London Stock Exchange in November 2003.

The trading price of ALSTOM's ADRs has recently fallen below the minimum of \$1 per ADR required in order to maintain the listing of the ADRs on the NYSE. The volume of ADR transactions is very low (approximately 1% of the overall trading in ALSTOM shares during the last six months). Therefore, after discussion with the NYSE, ALSTOM has decided not to take steps, such as to modify its current 1:1 ADR/ordinary shares exchange ratio, as would be required to return to compliance with the NYSE's continued listing criteria. ALSTOM expects that this will lead to suspension of trading of the ADRs on the NYSE.

ALSTOM will determine in the near future whether its ADR program will be continued. Should a decision be made to terminate the program, notice of the termination date would be mailed to the registered owners of the ADRs at least 30 days in advance. Following any such termination, the ADR owners would continue to be entitled for a period of one year to surrender their ADRs for the underlying ALSTOM ordinary shares in accordance with the Deposit Agreement, but would cease to be entitled to register transfers of the ADRs themselves.

ALSTOM will remain subject to SEC reporting requirements upon delisting.

Press enquiries: S. Gagneraud
(Tel. +33 1 47 55 25 87)
internet.press@chq.alstom.com

Investor relations: E. Châtelain
(Tel. +33 1 47 55 25 33)
investor.relations@chq.alstom.com